Preservative: 0.02% Sodium Azide; Constituents: 40% Glycerol, PBS. pH 7.2
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide: GPQPSHWAAGDGPTQERC, corresponding to N terminal amino acids 13-30 of Human Livin.
Immunogen affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Baculoviral Iap Repeat Containing 7,Kiap,Livin,Ml-Iap,Mliap,Rnf50,Birc7
Apoptosis, or programmed cell death, is related to many diseases, such as cancer. Apoptosis is triggered by a variety of stimuli including members in the TNF family and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. A novel member in the IAP protein family was recently identified and designated Livin and KIAP for kidney IAP. Livin / XIAP contains a single baculoviral IAP repeat (BIR) domain and a RING finger domain and has two isoforms termed Livin alpha and Livin beta. Transfection of Livin in cells resulted in protection from apoptosis induced by FADD, BAX, RIP, RIP 3 and DR6. Livin has direct interaction with several caspases including caspase 3, 7, and 9. Livin inhibits the activation of caspase 9 induced by Apaf 1, cytochrome c, and dATP. The two isoforms of Livin appear to have different functions and tissue distributions.